Drugs /

onc206

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for onc206

Onc206 has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating onc206, 2 are phase 1 (2 open).

H3F3A K28M is the most frequent biomarker inclusion criterion for onc206 clinical trials.

Central nervous system neoplasm, diffuse glioma, and diffuse midline glioma, H3 K27M-mutant are the most common diseases being investigated in onc206 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Onc206
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating onc206 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
onc 206, onc-206
Drug Target(s) [2]:
CLPP, DRD2, DRD3

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.